Browsing Tag
Akebia Therapeutics
2 posts
Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline
Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook.
FDA approves Akebia Therapeutics’ Vafseo for anemia in dialysis patients
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients,…